Adults age ≥ 18 ≤ 65 with a symptomatic ureteric stone

Assessed for eligibility during standard clinical consultation
1) Suitable for conservative management: stone dimension ≤ 10 mm within any segment of the ureter previously confirmed by CTKUB
2) Suitable for medical therapy (no contraindications to trial medication)

Excluded
Not meeting inclusion criteria

Consented
Eligible participants given trial information and asked for consent

Do not wish to participate

Baseline assessment
Pain: NRS
Quality of Life: EQ5D/SF36

Randomized
α-blocker vs Calcium channel blocker vs Placebo

α-blocker
Tamsulosin
(over encapsulated)
0.4mg/day/maximum 28 days

Calcium channel blocker
Nifedipine
(over encapsulated)
30mg/day/maximum 28 days

Placebo
1 capsule per day/maximum 28 days

4 weeks post randomization
Stone passage (no further interventions)
Pain: NRS
Health Status: EQ5D/SF36
Adverse events
Time to passage of stone
Use of analgesics

4 weeks post randomization
Stone passage (no further interventions)
Pain: NRS
Health Status: EQ5D/SF36
Adverse events
Time to passage of stone
Use of analgesics

4 weeks post randomization
Stone passage (no further interventions)
Pain: NRS
Health Status: EQ5D/SF36
Adverse events
Time to passage of stone
Use of analgesics

12 weeks post randomization
Additional treatments or surgery
Health Status: EQ5D/SF36
Adverse events
Time to passage of stone
Use of analgesics Health service use Participant costs

12 weeks post randomization
Additional treatments or surgery
Health Status: EQ5D/SF36
Adverse events
Time to passage of stone
Use of analgesics Health service use Participant costs

12 weeks post randomization
Additional treatments or surgery
Health Status: EQ5D/SF36
Adverse events
Time to passage of stone
Use of analgesics Health service use Participant costs